Product Code: GVR-4-68040-257-2
Dietary Supplement Contract Manufacturing Market Growth & Trends:
The global dietary supplements contract manufacturing market size is estimated to reach USD 121.2 billion by 2030, registering a CAGR of 12.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market involves the production of dietary supplements by a third-party manufacturer for another company. The manufacturer provides services, such as formulation, blending, mixing, encapsulation, tableting, packaging, and labeling of the supplements. The demand for dietary supplements has been increasing due to factors, such as rising health consciousness among consumers, an increasing aging population, changing lifestyles, and technological advancements. With the rise in chronic diseases and lifestyle-related disorders, people are becoming more proactive in maintaining their health. This has led to a surge in demand for dietary supplements that can help prevent or manage these conditions.
As a result, manufacturers are constantly developing new products and formulations to cater to this growing demand. The rise of e-commerce platforms and online sales channels has also contributed to market growth with the increasing popularity and accessibility of online shopping. Personalized nutrition is a growing trend in the dietary supplement industry. Consumers are increasingly seeking supplements tailored to their specific needs based on factors, such as age, gender, lifestyle, and genetic makeup. Contract manufacturers are responding to this trend by developing new technologies and processes to produce personalized supplements at scale. For instance, in March 2022, Ashland launched Nutrapress organic chewable base, designed for chewable dietary supplements. The organic base is a complete system for nutraceutical manufacturers and contains an organic binder, sweetener, flow aid, and lubricant.
Dietary Supplement Contract Manufacturing Market Report Highlights:
- The proteins & amino acid supplements product segment dominated the market in 2024. The growth can be attributed to the increased need for supplements that contain essential amino acids along with a growing product pipeline and easy availability of specialized expertise for the development of innovative products
- The tablet dosage form segment dominated the market in 2024. Some key factors contributing to the segment growth include the convenience, ease of use, and precise dosage control offered by tablets.
- North America was the dominant regional market in 2024, due to the presence of key players and developed contract manufacturing capacities in North American.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Dosage Form
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Dietary Supplements Contract Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market driver Analysis
- 3.3.2. Market restraint analysis
- 3.4. Technological Landscape
- 3.5. Pricing Analysis Model
- 3.6. Industry Analysis Tools
- 3.6.1. Porter's Five Forces Analysis
- 3.6.2. PESTEL Analysis
- 3.6.3. COVID-19 Impact Analysis
Chapter 4. Dietary Supplements Contract Manufacturing Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Dietary Supplements Contract Manufacturing Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Proteins and Amino Acid Supplements
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Multivitamin, Multi-Mineral, and Antioxidant Supplements
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Weight Management and Meal Replacer Supplements
- 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Other Supplements
- 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Dietary Supplements Contract Manufacturing Market: Dosage Form Estimates & Trend Analysis
- 5.1. Dosage Form Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Dietary Supplements Contract Manufacturing Market by Dosage Form Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Tablets
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Capsules
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Liquid Oral
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Powder In Sachet / Jar
- 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.9. Gummies
- 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.10. Others
- 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.2. Company/Competition Categorization
- 6.3. Vendor Landscape
- 6.3.1. List of key distributors and channel partners
- 6.3.2. Key customers
- 6.3.3. Key company heat map analysis, 2024
- 6.4. Company Profiles
- 6.4.1. Ashland
- 6.4.1.1. Company overview
- 6.4.1.2. Financial performance
- 6.4.1.3. Product benchmarking
- 6.4.1.4. Strategic initiatives
- 6.4.2. Glanbia plc
- 6.4.2.1. Company overview
- 6.4.2.2. Financial performance
- 6.4.2.3. Product benchmarking
- 6.4.2.4. Strategic initiatives
- 6.4.3. Lonza Group Ltd
- 6.4.3.1. Company overview
- 6.4.3.2. Financial performance
- 6.4.3.3. Product benchmarking
- 6.4.3.4. Strategic initiatives
- 6.4.4. CAPTEK Softgel International Inc.
- 6.4.4.1. Company overview
- 6.4.4.2. Financial performance
- 6.4.4.3. Product benchmarking
- 6.4.4.4. Strategic initiatives
- 6.4.5. Catalent, Inc
- 6.4.5.1. Company overview
- 6.4.5.2. Financial performance
- 6.4.5.3. Product benchmarking
- 6.4.5.4. Strategic initiatives
- 6.4.6. Trividia Manufacturing Solutions, Inc.
- 6.4.6.1. Company overview
- 6.4.6.2. Financial performance
- 6.4.6.3. Product benchmarking
- 6.4.6.4. Strategic initiatives
- 6.4.7. Biotrex Nutraceuticals
- 6.4.7.1. Company overview
- 6.4.7.2. Financial performance
- 6.4.7.3. Product benchmarking
- 6.4.7.4. Strategic initiatives
- 6.4.8. Martinez Nieto.
- 6.4.8.1. Company overview
- 6.4.8.2. Financial performance
- 6.4.8.3. Product benchmarking
- 6.4.8.4. Strategic initiatives
- 6.4.9. Menadiona
- 6.4.9.1. Company overview
- 6.4.9.2. Financial performance
- 6.4.9.3. Product benchmarking
- 6.4.9.4. Strategic initiatives
- 6.4.10. NutraScience Labs
- 6.4.10.1. Company overview
- 6.4.10.2. Financial performance
- 6.4.10.3. Product benchmarking
- 6.4.10.4. Strategic initiatives
- 6.4.11. Nutrivo LLC,
- 6.4.11.1. Company overview
- 6.4.11.2. Financial performance
- 6.4.11.3. Product benchmarking
- 6.4.11.4. Strategic initiatives
- 6.4.12. Gemini Pharmaceuticals
- 6.4.12.1. Company overview
- 6.4.12.2. Financial performance
- 6.4.12.3. Product benchmarking
- 6.4.12.4. Strategic initiatives
- 6.4.13. Biovencer Healthcare Pvt Ltd
- 6.4.13.1. Company overview
- 6.4.13.2. Financial performance
- 6.4.13.3. Product benchmarking
- 6.4.13.4. Strategic initiatives
- 6.4.14. Rain Nutrience
- 6.4.14.1. Company overview
- 6.4.14.2. Financial performance
- 6.4.14.3. Product benchmarking
- 6.4.14.4. Strategic initiatives
- 6.4.15. Vantage Nutrition (ACG group
- 6.4.15.1. Company overview
- 6.4.15.2. Financial performance
- 6.4.15.3. Product benchmarking
- 6.4.15.4. Strategic initiatives
- 6.4.16. LiquidCapsule
- 6.4.16.1. Company overview
- 6.4.16.2. Financial performance
- 6.4.16.3. Product benchmarking
- 6.4.16.4. Strategic initiatives
- 6.4.17. DCC plc
- 6.4.17.1. Company overview
- 6.4.17.2. Financial performance
- 6.4.17.3. Product benchmarking
- 6.4.17.4. Strategic initiatives
- 6.4.18. Nature's Value
- 6.4.18.1. Company overview
- 6.4.18.2. Financial performance
- 6.4.18.3. Product benchmarking
- 6.4.18.4. Strategic initiatives
- 6.4.19. MPI NutriPharma BV
- 6.4.19.1. Company overview
- 6.4.19.2. Financial performance
- 6.4.19.3. Product benchmarking
- 6.4.19.4. Strategic initiatives
- 6.4.20. FAVEA Czech Republic (Favea)
- 6.4.20.1. Company overview
- 6.4.20.2. Financial performance
- 6.4.20.3. Product benchmarking
- 6.4.20.4. Strategic initiatives
- 6.4.21. MediGrun Naturprodukte GmbH (MediGrun)
- 6.4.21.1. Company overview
- 6.4.21.2. Financial performance
- 6.4.21.3. Product benchmarking
- 6.4.21.4. Strategic initiatives